ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS, oprettet i 2005 (United States), fra 496 søstermærker og 17478 konkurrerende mærker. Mærket ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS er ejet af BRISTOL-MYERS SQUIBB COMPANY, et selskab noteret i New York. ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS's sektor er Lægemiddelproducenter.

ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS er et mærke tilhørende BRISTOL-MYERS SQUIBB COMPANY (BMY) Nyheder

International depositum : 2005 Erhvervssektor Lægemiddelproducenter

Alle nyheder Marketscreener-logo
BRISTOL-MYERS SQUIBB COMPANY (ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS)

loader
børs: Mere information om BRISTOL-MYERS SQUIBB COMPANY (ARRIVE - ABATACEPT RESEARCHED IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE ANTI-TNF RESPONSE TO VALIDATE EFFECTIVENESS) Marketscreener-logo